Clinical pharmacology studies in UK Phase 1 units: An AHPPI survey 1999-2000

British Journal of Clinical Pharmacology

Volumn 57, Issue 1, 2004, Pages 76-79

  Calder, N ^a   Boyce, M ^b   Posner, J ^c   Sciberras, D ^d  

^a Merck Sharp & Dohme Limited   (United Kingdom)

^b CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^c Amersham Health ^*

^d Amersham Health   (United Kingdom)

Author keywords

AHPPI; Phase I; Survey

Indexed keywords

CLINICAL PHARMACOLOGY; CLINICAL RESEARCH; DRUG APPROVAL; DRUG INDUSTRY; DRUG RESEARCH; HEALTH SURVEY; HUMAN; NORMAL HUMAN; ORGANIZATION; PRIORITY JOURNAL; PROFESSIONAL STANDARD; QUESTIONNAIRE; REVIEW; TIME; UNITED KINGDOM;

BIOMEDICAL RESEARCH; CLINICAL TRIALS, PHASE I; DRUG INDUSTRY; ETHICS COMMITTEES, CLINICAL; ETHICS COMMITTEES, RESEARCH; GREAT BRITAIN; HUMANS; PHARMACOLOGY, CLINICAL; QUESTIONNAIRES;

EID: 0346057806     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01961.x     Document Type: Review

References (6)

1. Directive, 2001/20/EC. Off J Eur Comm 2001; L121: 34-44.
2. Health and Medicines Act. (c. 49). London: HMSO, 1988.
3. Sciberras D, Calder N, Boyce M, Posner J. AHPPI survey of UK phase I units, 1999-2000. Br J Clin Pharmacol 2003; 55: 433.
4. Boyce M, Dunn K, Lewis Y, Wicks J, Warrington S. Potential impact of the European Clinical Trials Directive on UK phase I studies. Br J Clin Pharmacol 2002; 53: 417P.
5. Boyce M, Warrington S. Analysis of 312 studies of investigational medicinal products in healthy subjects to assess the impact of the European Union Clinical Trials Directive. Int J Pharmaceut Med 2002; 16: 179-83.
6. Pharmaceutical Industry Competitiveness Task Force. London: Department of Health and ABPI, March 2001.